Over the next 5 years, CDC will work with many different partners to help implement:

• Phase III trials in Thailand of an HIV vaccine based on the glycoprotein-20 antigen developed by the VaxGen company

• Studies to evaluate the effectiveness of 7-valent pneumoccocal conjugate vaccines on
  • Herd immunity among Native American communities that have high rates of invasive disease. This is a phase III, cluster-randomized trial of conjugate pneumococcal vaccine conducted in collaboration with Johns Hopkins School of Public Health.
  • Nasopharyngeal carriage of pneumococci in Alaska
  • Invasive pneumococcal disease throughout the United States, using the Active Bacterial Core Surveillance (ABCs) system.

• Phase III trial in the Gambia of a 9-valent conjugate pneumococcal vaccine against all-cause mortality and acute-respiratory-infection-specific mortality, conducted in collaboration with the Medical Research Council-Gambia, USAID, NIH, the Bill and Melinda Gates Children’s Vaccine Program, and WHO’s Vaccine Development, Vaccines and Biologicals program.

• USAID-supported Phase I trials of two vaccines against Schistosomiasis mansoni, conducted by the Schistosome Vaccine Development Project, a partnership involving the Government of Egypt, CDC, NIH/NIAID, NAMRU-3, academic centers, and private industry.

• A multisite rotavirus vaccine trial in Southeast Asian countries using an attenuated human rotavirus vaccine produced in India.